NorthStrive Biosciences expands AI drug discovery pact with Yuva
NorthStrive Biosciences, a subsidiary of NASDAQ-listed PMGC Holdings, has amended its development and licence agreement with Yuva Biosciences to launch a structured three-phase Expansion Programme. The programme will advance four small-molecule compounds, identified by Yuva's MitoNova AI platform, toward a nominated lead candidate and a designated backup, with a focus on cardiac disease and obesity indications.
The four compounds were previously reported, in a July 2026 update, to have shown statistically significant increases in ANT1, a mitochondrial protein involved in skeletal muscle energy metabolism, in primary human skeletal muscle cells. That in vitro readout constituted what the companies termed "positive Phase III results" within their internal discovery pipeline. The Expansion Programme now seeks to confirm whether that ANT1 induction holds up in differentiated human myotubes, a more physiologically mature cell model.
Three-phase structure
The expansion unfolds sequentially. The first phase establishes a qualified assay and standard operating procedure. The second confirms ANT1 induction and generates ranked go/no-go data for each of the four compounds. The third profiles the lead candidates against Yuva's Mitochondrial Biogenesis Panel, quantifies cellular ATP output, and delivers an integrated mechanism-of-action hypothesis alongside the lead nomination. The programme is expected to take approximately six months.
The amendment also strengthens NorthStrive's exclusive field of use, clarifying definitions for both cardiac disease and obesity and aligning the programme with the company's stated interest in muscle-preservation strategies relevant to patients using GLP-1 receptor agonist therapies. A right of first refusal to negotiate an exclusive licence across the broader cardiometabolic field has also been added, applicable during the agreement term and for one year following completion of the third expansion phase.
Market context
The cardiometabolic space sits at the intersection of two of the most commercially active areas in drug development. Obesity therapeutics have attracted substantial capital and competitive intensity following the commercial success of GLP-1 agonists such as semaglutide, while cardiac disease remains a leading cause of mortality globally and a persistent focus for both large pharma and smaller biotechs. Mitochondrial biology as a therapeutic target is a less well-trodden path, with a relatively modest number of programmes in clinical development, though interest has grown alongside broader recognition of metabolic dysfunction in cardiometabolic disease.
NorthStrive and Yuva remain at an early preclinical stage. The four compounds have been assessed only in vitro, and the companies have been transparent that results in cell-based models do not guarantee reproducibility in animal studies or human clinical trials. No IND has been filed, and the programme's stated endpoint is lead nomination, not a regulatory submission. Investors should note that the "Phase III" terminology used by the companies refers to internal discovery phases, not clinical-stage trials as the term is conventionally understood in drug development.
Yuva Biosciences' commercial footprint currently comprises consumer wellness products incorporating its AI-discovered compounds, including offerings under the BosleyMD and Rerise Health brands. The translation from consumer supplements to regulated therapeutics involves a materially different regulatory and clinical-development burden. NorthStrive's lead asset, EL-22, is described as an engineered probiotic candidate separately targeting muscle preservation in GLP-1 users; the ANT1-targeting small-molecule programme is distinct from that effort.
The next milestone to watch is confirmation data from Expansion Phase II, expected to be released upon completion. Lead compound nomination is anticipated at the close of Expansion Phase III, approximately six months from programme commencement.